Ask AI
ProCE Banner Series

Optimizing Use of BTK Inhibitors in CLL/SLL and MCL for Managed Care Professionals

Register now for this interactive, case-based webinar to learn more about the new and emerging strategies in the optimal use of BTK inhibitors for the management of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL), including discussions about the latest data on recent advances in the personalization of care of these patients. After the meeting, download the associated slideset for use in your practice.

To Register: Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  ACPE-P
Who Should Attend

This program is intended for pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with CLL/SLL or MCL, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice. 

All Events

Optimizing Use of BTK Inhibitors in CLL/SLL and MCL for Managed Care Professionals

Past Events

January

18

2024

12:00 PM - 1:30 PM Eastern Time (ET)

Virtual

January

25

2024

3:00 PM - 4:30 PM Eastern Time (ET)

Virtual

Topics

  • Welcome and Introduction
  • Overview of BTK inhibitors
  • Clinical Applications of BTK inhibitors Data for Patients With CLL/SLL and MCL
  • Future of BTK Inhibitor therapy: Clinical Implications of Ongoing Studies and Application of New and Emerging Data
  • Managed Care Strategies for Evidence-Based, Equitable Care to Optimize Treatment Outcomes
  • Final Thoughts and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Program Overview
This program will provide expert perspectives on the role of BTK inhibitors in the personalized care of patients with CLL/SLL and MCL using clinical case studies to illustrate how BTK inhibitors are selected and sequenced to maximize adherence, compliance, efficacy, and safety while ensuring cost-effective and accessible integration of these agents into managed care decision-making. 

Goal Statement
The goal of this program is to improve the knowledge and competence of pharmacist learners regarding the evidence-based implementation of BTKi-based regimens for patients with CLL/SLL or MCL. 

Target Audience
This program is intended for pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with CLL/SLL or MCL, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate differences between BTKi, including covalent and noncovalent BTKi, in terms of molecular characteristics, selectivity, clinical data, approved indications, safety profiles, and place in therapy
  • Develop BTKi-based therapeutic strategies for patients with CLL/SLL or MCL based on the latest clinical data and patient- and disease- specific factors
  • Determine strategies to promote equitable, evidence-based care that ensures cost-effective and accessible integration of BTKi into managed care decision-making

Accreditation

CE Accreditation

Pharmacists

ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-23-032-L01-P has been assigned to this live application-based activity (initial release date 11/27/2023). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC

This activity is supported by an educational grant from Lilly.

For customer support please email: customersupport@clinicaloptions.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191